Keryx Biopharmaceuticals (NASDAQ:KERX) Posts Earnings Results, Misses Estimates By $0.02 EPS

Keryx Biopharmaceuticals (NASDAQ:KERX) issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.02), Bloomberg Earnings reports.

Shares of KERX traded up $0.07 during mid-day trading on Friday, hitting $3.41. 409,200 shares of the company traded hands, compared to its average volume of 1,173,376. Keryx Biopharmaceuticals has a 1-year low of $2.93 and a 1-year high of $8.07. The company has a quick ratio of 1.40, a current ratio of 2.28 and a debt-to-equity ratio of -3.16. The company has a market cap of $404.74 million, a P/E ratio of -3.88 and a beta of 2.59.

KERX has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 2nd. Maxim Group set a $9.00 target price on shares of Keryx Biopharmaceuticals and gave the company a “buy” rating in a research note on Thursday, May 10th. HC Wainwright initiated coverage on shares of Keryx Biopharmaceuticals in a research note on Thursday, June 28th. They issued a “buy” rating and a $9.00 price objective for the company. Citigroup lowered their price objective on shares of Keryx Biopharmaceuticals from $4.75 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, August 9th. Finally, BidaskClub raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 11th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $6.25.

A hedge fund recently raised its stake in Keryx Biopharmaceuticals stock. Bank of New York Mellon Corp increased its holdings in Keryx Biopharmaceuticals (NASDAQ:KERX) by 10.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,056,811 shares of the biopharmaceutical company’s stock after buying an additional 102,014 shares during the quarter. Bank of New York Mellon Corp owned about 0.88% of Keryx Biopharmaceuticals worth $3,974,000 at the end of the most recent reporting period. 59.53% of the stock is currently owned by hedge funds and other institutional investors.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

Recommended Story: How Short Selling Works

Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply